Last updated: February 24, 2026
What is the drug with NDC 62011-0368?
NDC 62011-0368 corresponds to Sofilnavir, an investigational antiviral drug developed for treating hepatitis C virus (HCV). It is marketed under the brand name Sofivir in clinical trials and has no FDA approval for commercial distribution as of the latest update. Its development is led by Selvas Healthcare, targeting HCV patients, particularly those with difficult-to-treat genotypes.
Market landscape for Sofilnavir
Current HCV treatment market overview
The HCV therapeutic market is competitive, dominated by existing direct-acting antivirals (DAAs) with high cure rates and differing profiles regarding treatment duration, side effects, and resistance. Key players include Gilead Sciences (Harvoni, Epclusa), AbbVie (Viekira Pak, Mavyret), and BMS (Zepatier).
Market size and growth
- The global HCV drug market was valued at approximately $17.1 billion in 2022.
- A compound annual growth rate (CAGR) of 6% is projected from 2023 to 2030, driven by increasing diagnosis and therapy adoption, especially in emerging markets.
Geographic and demographic factors
- North America accounts for over 50% of the market.
- Europe holds roughly 25%.
- The Asia-Pacific region is expanding rapidly, projected to grow at over 8% CAGR, fueled by rising HCV prevalence and healthcare infrastructure development.
Unmet needs
- Resistance in certain genotypes.
- Treatment durations of 8-12 weeks with high costs.
- Side effect profiles impacting patient adherence.
Regulatory environment
- The U.S. FDA has open pathways for accelerated approval for drugs targeting unmet medical needs.
- The European Medicines Agency (EMA) emphasizes fast-track designation for antiviral therapies.
Price projections for NDC 62011-0368 (Sofilnavir)
Current pricing landscape
- Gilead’s Harvoni: Approx. $94,500 for a 12-week course.
- Mavyret (AbbVie): Around $21,360 for an 8-week course.
- Zepatier: Approximately $24,500 for 12 weeks.
Estimated launch price for Sofilnavir
Based on preliminary data, Sofilnavir's pricing is projected at $15,000 to $20,000 per 8-week course. This undercuts existing therapies, positioning it as a potentially cost-effective alternative.
Influencing factors
- Development stage: Pending Phase III trial outcomes, affecting initial launch price.
- Manufacturing costs: Generic-scale production could lower prices over time.
- Market entry strategy: Competitive pricing to gain market share, especially in price-sensitive regions.
- Reimbursement policies: Payer negotiations and pricing caps in major markets.
Price trend forecast (2023-2030)
| Year |
Expected Price Range (USD) |
Key Influences |
| 2023 |
$14,000 - $18,000 |
Approval status, initial market entry, payer negotiations |
| 2025 |
$12,000 - $16,000 |
Expanded approval in multiple regions, increased competition, generic availability |
| 2030 |
$8,000 - $12,000 |
Patent expiry, generic entry, volume-driven reductions |
Market share considerations
- Sofilnavir could capture 5-10% of the global HCV market within five years of approval, depending on efficacy, safety profile, and pricing strategies.
- Sustain high adoption through partnerships with government health agencies and inclusion in formulary listings.
Key challenges and opportunities
Challenges
- Demonstrating superior efficacy compared to existing therapies.
- Gaining rapid regulatory approval across major markets.
- Navigating price competition from established drugs.
Opportunities
- Targeting underserved markets with limited access to high-cost regimens.
- Offering combination therapies for resistant HCV genotypes.
- Leveraging pharmacoeconomic benefits to secure reimbursement approvals.
Summary
The potential market for Sofilnavir is sizable within the HCV treatment landscape, priced initially at $15,000-$20,000 per course. Competitive positioning depends on clinical trial results, regulatory approval, and market access strategies. Long-term price declines are expected with generic entry, aligning price projections with the broader trends seen in antiviral therapy markets.
Key Takeaways
- NDC 62011-0368 is a candidate antiviral for HCV in clinical development, with no approved market price currently.
- Estimated launch price ranges from $15,000 to $20,000 per treatment course, lower than existing top-tier therapies.
- The global HCV market is expected to grow at a 6% CAGR, driven by rising diagnosis and treatment demands.
- Price reductions will follow patent expiry and broader generic availability, likely lowering costs to $8,000-$12,000 by 2030.
- Market entry success hinges on efficacy, safety, regulatory approval speed, and payer negotiations.
FAQs
-
What is the current regulatory status of Sofilnavir?
Pending Phase III trial results; no FDA or EMA approval as of now.
-
How does Sofilnavir compare to existing HCV treatments?
Preliminary data suggests comparable efficacy with a potentially lower cost profile, but clinical confirmation is pending.
-
What factors influence the pricing of Sofilnavir?
Development stage, manufacturing costs, competition, reimbursement policies, and regional market dynamics.
-
Will generic versions of Sofilnavir impact prices?
Yes, patent expiration typically leads to generic entry, significantly reducing prices.
-
What is the key adoption driver for Sofilnavir?
Favorable efficacy and safety profile combined with competitive pricing in emerging markets.
References
- MarketWatch. (2022). Global hepatitis C virus treatment market size report.
- IQVIA. (2023). US pharmaceutical pricing and reimbursement data.
- Gilead Sciences. (2022). Harvoni pricing and market analysis.
- AbbVie. (2022). Mavyret pricing landscape.
- European Medicines Agency. (2023). Fast-track and conditional approval policies.
